Halozyme Therapeutics | HALO - Operating Expenses



Halozyme Therapeutics reported $123.28M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amarin USD 58.77M 56.06M Mar/2025
Amgen USD 6.52B 337M Jun/2025
Baxter International USD 2.54B 29M Jun/2025
Cytokinetics USD 178.28M 21.06M Jun/2025
DBV Technologies USD 41.11M 13.74M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Halozyme Therapeutics USD 123.28M 48K Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
MannKind USD 65.86M 9.8M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
United Therapeutics USD 521.7M 110.1M Jun/2025